Fritextsökning
Innehållstyper
-
Thumbs down for lecanemab in the EU – “Very surprised”
The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...
-
ZEISS presents the "Quality Innovation Days"
The digital event for metrology and software.
-
The First Multi-Technology System from ZEISS
Microscope and measuring machine in one.
-
Enhance your expertise with your measuring software
Discover the training options in our ZEISS Metrology Portal.
-
The physician at the tech giant: “Observations in the emergency room made my mind up”
When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite...
-
A new scientific event in Gothenburg
Life Science Sweden is holding an event in Gothenburg for the first time.
-
Mikael Kubista back with new venture after turbulent exit
Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...
-
ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions
ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS 2025 in Copenhagen.
-
“Don’t postpone the transition to IVDR”
Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...
-
Save the dates: ZEISS Quality Innovation Summit, October 22-24
Embark on a journey to the future of metrology.
-
Positive EMA Decision for BioArctic's New Drug Candidate
Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).
-
The impact of the recession on the Swedish medtech sector
We need health care regardless of whether the economy is good or bad, but the current recession also affects the Medtech sector.
-
Setback for pharmaceutical companies in the Zantac case
A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.
-
Drug development booms in Medicon Valley
When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...
-
Assignment: Facilitate the retention of foreign researchers
A newly appointed public inquiry is to develop measures to make attracting and retaining foreign doctoral students and researchers in Sweden easier.
-
Johan Pehrson takes over the responsibility for research policy in Sweden
The Liberals' party leader Johan Pehrson takes over the assignment as Minister for Education. This was announced by Prime Minister Ulf Kristersson (M) on Tuesday last week.
-
Explore the latest trends and innovations in quality assurance and manufacturing
ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.
-
The dock that “thinks” for itself
The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...
-
The new Swedish life science strategy – “It will consolidate Sweden as a leader”
Clinical trials and precision health are emphasised as key areas in the new national life science strategy.
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
Science Sweden has spoken to Swedish researchers in Alzheimer’s who voice cautious hope but also see further challenges.
-
No longer afraid of the dentist.
Teaching robot with piezo technology
-
One last chance to register for the premier metrology event in 2024
ZEISS QUALITY INNOVATION SUMMIT.
-
Success for Genmab's antibody-drug conjugate
The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
BREAKING